ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 524

Predictors of Mortality in RA Patients before Biologic Therapy

Debora Cordeiro Rosario1, Camila Nobre Bulhoes1, Rodrigo Peres Toledo1, Karina Bonfiglioli2, Ana C.M. Ribeiro3, Julio C. B. Moraes2, Carla G.S. Saad2, Clovis A Silva4, Eloisa Bonfa5 and Nadia E Aikawa2, 1Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic drugs, morbidity and mortality and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 5, 2017

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Several studies have evaluated mortality risk factors in rheumatoid arthritis (RA) but that are no data regarding baseline predictors of mortality in patients under biologic therapy. In fact, definition of these predictors is difficult due to many confounding variables such as age, gender, biologic drug itself and its duration. Therefore, the aim of this study was to identify clinical and laboratory baseline predictors of death in RA patients matched for all these parameters under biologic treatment.

Methods: This was a retrospective observational study that included all deceased RA patients (ACR classification criteria) regularly followed in the biologic therapy center of Rheumatology Division of a tertiary university hospital. All relevant parameters were evaluated using an electronic chart database established from 2007 to 2016. All biologic drugs, including subcutaneous and intravenous agents, are regularly administered in-hospital. A control group of RA patients under biologic treatment matched for gender, age, biologic drug and its duration was included. Demographic data, comorbidities, clinical and laboratorial findings and concomitant treatment were assessed at the baseline of last biologic drug and at the last visit before death.

Results: During the study, 22/436 (5%) RA patients died after biologic therapy start. Causes of death included infections in 18 (82%), complications of pulmonary fibrosis in 2 (9%), subarachnoid hemorrhage in 1 (4.5%) and hemorrhagic stroke in 1 (4.5%). Deceased and survivors patients were comparable with regard to current age (57 vs. 57 years, p=0.34), male gender (27% vs. 27%, p=1.0) and last biologic duration (12 vs. 10 months, p=0.51). Analysis of baseline therapeutic parameters of the last biologic drug in the deceased group compared to survival groups revealed similar median number of biologic agents (p=0.94), need of at least one switching to another biologic agent (68% vs. 63, P=0.79) and frequencies of other drugs [prednisone (p=0.25), methotrexate (p=0.8), leflunomide (p=0.79) or sulfasalazine (p=0.11)]. Likewise, clinical and laboratorial characteristics were alike in both groups [Disease Activity Score in 28 joints (DAS28) (4.75 vs 4.96, p=0.75), HAQ (1.75 vs. 1.185, p=0.37), RF (68% vs. 84%, p=0.2) and anti-CCP (18% vs. 21%, p=1.0]. Concerning associated comorbidities, deceased patients had a significantly higher frequency of chronic renal failure (18% vs. 2%, p=0.041) and a trend for a higher frequency of osteoporosis (59% vs. 33%, p=0.062) compared to the control group. Further analysis of all parameters at last visit before death demonstrated that deceased group had a higher DAS28 (3.84 vs. 3.06, p=0.05) and Health Assessment Questionnaire (HAQ) (1.563 vs. 1.0, p=0.0054).

Conclusion: The present study design with rigorous control for confounding factors identified solely chronic renal failure and possibly osteoporosis (in non elderly population) as the most important baseline predictors of mortality in RA patients starting biologic therapy in a real life setting. High RA activity and severity at the last visit before death are short-term predictors of death in patients already under biologic therapy.


Disclosure: D. C. Rosario, None; C. N. Bulhoes, None; R. P. Toledo, None; K. Bonfiglioli, None; A. C. M. Ribeiro, None; J. C. B. Moraes, None; C. G. S. Saad, None; C. A. Silva, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP #2014/14806-0 and 2015/03756-4 to CAS), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq 303422/2015-7 - 1A to CAS), 2; E. Bonfa, None, 2; N. E. Aikawa, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4 to NEA), 2.

To cite this abstract in AMA style:

Rosario DC, Bulhoes CN, Toledo RP, Bonfiglioli K, Ribeiro ACM, Moraes JCB, Saad CGS, Silva CA, Bonfa E, Aikawa NE. Predictors of Mortality in RA Patients before Biologic Therapy [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/predictors-of-mortality-in-ra-patients-before-biologic-therapy/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-mortality-in-ra-patients-before-biologic-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.